Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 7/20 | 0.67 |
| ▸ | NPC1 | O15118 | 5/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.67 |
| ▸ | RAB9A | P51151 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 3/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | MMP1 | P03956 | 1/20 | 0.54 |
| ▸ | MMP3 | P08254 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4017465 | 1.00 | EPHX1 (0.67) | EPHX1NPC1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL529370 | 1.00 | EPHX1 (0.67) | EPHX1NPC1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL28034199 | 1.00 | EPHX1 (0.67) | EPHX1NPC1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL4017458 | 1.00 | EPHX1 (0.67) | EPHX1NPC1SMN1; SMN2RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL11512953 | 0.97 | EPHX1 (0.64) | EPHX1NPC1SMN1; SMN2RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL11155165 | 0.97 | EPHX1 (0.64) | EPHX1NPC1SMN1; SMN2RAB9AALDH1A1 | |
| Bromide SCHEMBL31210076 | 0.97 | EPHX1 (0.64) | EPHX1NPC1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL374902 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL28662905 | 0.94 | EPHX1 (0.59) | EPHX1NPC1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL19282177 | 0.93 | EPHX1 (0.58) | EPHX1NPC1SMN1; SMN2RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903979-B1 | NOVEL COMPOUNDS, THEIR PREPARATION AND THEIR USES | INHIBIKASE THERAPEUTICS INC (US) | 2020-08-19 | — | — | EP | claimed |
| US-6323195-B1 | ENZYME INHIBITORS AND COGNITION ACTIVATORS | AVENTIS PHARMACEUTICALS INC. | 2001-11-27 | — | — | US | claimed |
| EP-0653427-A1 | Galanthamine derivatives, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1995-05-17 | — | — | EP | claimed |
| CN-103987707-B | The base heterocyclic radical benzamide compound of pyrazoles 4 and application method | 霍夫曼-拉罗奇有限公司 | 2017-11-07 | — | — | CN | disclosed |
| WO-2014151719-A1 | SUBLINGUAL FORMULATIONS INCLUDING GERANYLGERANYLACETONE AND GERANYLGERANYLACETONE DERIVATIVES | COYOTE PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| EP-1498411-B9 | DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2013-12-04 | — | — | EP | disclosed |
| EP-1498411-B1 | DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-8138182-B2 | Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20100087442-A1 | DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD (JP) | 2010-04-08 | — | — | US | disclosed |
| US-7655804-B2 | N-[(1S)-3-{(2Z)-2-[(4R)-3,4-dimethyl-1,3-thiazolidin-2-ylidene]hydrazino}-2,3-dioxo-1-(tetrahydro-2H-pyran-4-yl)propyl]cycloheptanecarboxamide; cysteine protease inhibitors; for the treatment of inflammatory, immune, ischemic, respiratory,circulatory, neuronal, blood, hepatic and metabolic diseases | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-02-02 | — | — | US | disclosed |
| US-20060111303-A1 | Diketohydrazine derivative compounds and drugs contaiing the compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-25 | — | — | US | disclosed |
| EP-1498411-A1 | DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-01-19 | — | — | EP | disclosed |
| US-6323195-B1 | ENZYME INHIBITORS AND COGNITION ACTIVATORS | AVENTIS PHARMACEUTICALS INC. | 2001-11-27 | — | — | US | disclosed |
| EP-1020470-A2 | Galanthamine derivatives, a process for their preparation and their use as medicaments | SYNAPTECH, INC. (US) | 2000-07-19 | — | — | EP | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5777108-A | ALZHEIMER*S DISEASE | HOECHST MARION ROUSSEL, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
| EP-0653427-A1 | Galanthamine derivatives, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1995-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087442-A1 | DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT | SERPINB1, CTSZ, ELANE | EPHX1 828/4885NPC1 226/4885SMN1; SMN2 1513/4885 |
| US-20060111303-A1 | Diketohydrazine derivative compounds and drugs contaiing the compounds as the active ingredient | SERPINB1, CTSZ, SERPINE1 | EPHX1 1142/4885NPC1 267/4885SMN1; SMN2 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.